Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e61-e63. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0878

View: 396 Download: 16

Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e52-e54. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0815

View: 476 Download: 22

Letter to the Editor

Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Xiao-Song Li, Xi-Ping Shen, Hang Li

Clin Mol Hepatol. 2025;31(1):e15-e16. Published online September 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0784

View: 468 Download: 27

Editorial

MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Rex Wan-Hin Hui, Lung-Yi Mak

Clin Mol Hepatol. 2025;31(1):290-292. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0630

View: 397 Download: 14

Original Article

Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis

Young Eun Chon, Young-Joo Jin, Jihyun An, Hee Yeon Kim, Miyoung Choi, Dae Won Jun, Mi Na Kim, Ji Won Han, Han Ah Lee, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2024;30(Suppl):S117-S133. Published online August 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0392

View: 1891 Download: 125

Reply to Correspondence

Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Jae Hyun Bae

Clin Mol Hepatol. 2024;30(4):1047-1049. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0666

View: 1126 Download: 53

Correspondence

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(4):1019-1022. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0471

View: 1189 Download: 58

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2024;30(4):989-991. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0705

View: 896 Download: 37 Crossref: 1

Letter to the Editor

Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):974-977. Published online July 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0417

View: 1497 Download: 74

Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):962-964. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264

View: 1486 Download: 100 Web of Science: 1 Crossref: 4

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):959-961. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0233

View: 1372 Download: 69 Web of Science: 2 Crossref: 3

Editorial

Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”

Junjie Yu

Clin Mol Hepatol. 2024;30(4):721-723. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0443

View: 1276 Download: 58 Web of Science: 1

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):705-708. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0372

View: 1623 Download: 63 Web of Science: 2 Crossref: 2

Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Jae Hyun Bae

Clin Mol Hepatol. 2024;30(4):665-668. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0562

View: 1238 Download: 87 Web of Science: 2 Crossref: 2

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 2462 Download: 161 Web of Science: 6 Crossref: 4

Original Article

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park

Clin Mol Hepatol. 2024;30(3):487-499. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0145

View: 3340 Download: 247 Web of Science: 1 Crossref: 2

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 4856 Download: 281 Web of Science: 9 Crossref: 11

Letter to the Editor

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 2296 Download: 62 Crossref: 1

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2861 Download: 140 Web of Science: 6 Crossref: 7

Editorial

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 2576 Download: 92 Web of Science: 1 Crossref: 2

Snapshot

Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease

Young Chang, Soung Won Jeong, Jae Young Jang

Clin Mol Hepatol. 2024;30(1):129-133. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0356

View: 3427 Download: 170 Crossref: 4

Correspondence

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(1):126-128. Published online November 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0500

View: 1957 Download: 47

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):124-125. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0470

View: 2051 Download: 50 Web of Science: 1 Crossref: 2

Letter to the Editor

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 2554 Download: 57 Web of Science: 2 Crossref: 1

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji

Clin Mol Hepatol. 2024;30(1):113-117. Published online November 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0440

View: 2540 Download: 79 Web of Science: 3 Crossref: 2

Original Article

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review

George Chen, Bubu Banini, Albert Do, Joseph K. Lim

Clin Mol Hepatol. 2023;29(Suppl):S319-S332. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0366

View: 4145 Download: 110 Web of Science: 6 Crossref: 6

Review

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0329

View: 6562 Download: 307 Web of Science: 15 Crossref: 19

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 4147 Download: 219 Web of Science: 12 Crossref: 16

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 4095 Download: 127 Web of Science: 8 Crossref: 8

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 4531 Download: 138 Web of Science: 6 Crossref: 7

1 | 2 | 3 | 4 | 5 | 6 |

Viewed By 6147	MAFLD: How is it different from NAFLD?
Viewed By 5249	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4973	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4166	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3941	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 154	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search